Suraj Bansal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Suraj Bansal has a total of 141 co-authors. Here are the top co-authors by number of shared publications:
- John E. Dick
Department of Molecular Genetics, University of Toronto
43 shared publications - Mark David Minden
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
43 shared publications - Andy G. X. Zeng
Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
41 shared publications - Hyerin Kim
Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
25 shared publications - James A. Kennedy
Odette Cancer Centre, Sunnybrook Health Sciences Center, Toronto, Canada
25 shared publications - Amanda Mitchell
Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
24 shared publications
Latest Publications
- Open Access
- 7 May 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (19) , 2238-2251
A stem and progenitor cell–derived gene expression signature is prognostic for survival in myelofibrosis
In this study, we hypothesized that transcriptomic features among disease-driving hematopoietic stem and progenitor cells (HSPC) could improve current paradigms for risk stratification in myelofibrosis (MF). Therefore, we performed bulk RNA sequencing (RNA-seq) of blood from 358 patients with MF, split into training and test cohorts. Single-cell RNA-seq data from Lin–CD34+ MF HSPCs were used to guide the development of a prognostic model trained on the bulk RNA-seq data. A NanoString assay was used to validate our final model in 2 independent cohorts of patients with MF. We identified a 24-gene weighted-sum expression score (MPN24) that was prognostic of overall survival (OS). In 2 independent cohorts of 170 and 100 patients with MF, MPN24-high scoring patients had worse 5-year OS compared with MPN24-low scoring patients (25.5% vs 86.9%, hazard ratio [HR] = 9.81, P = 4.0e−11 and 23.5% vs 75.9%, HR, 6.40, P = 1.8e−7, respectively). MPN24-high was also associated with clinical, mutation and karyotypic features known to confer adverse risk in MF. The MPN24 score retained independent prognostic significance in multivariable analysis incorporating these covariates and existing risk stratification models including Dynamic International Prognostic Scoring System (DIPSS), DIPSS plus, Mutation-Enhanced International Prognostic Score System (MIPSS70), and MIPSS70 plus version 2.0, adding significant prognostic value to these risk stratification models (P = 1.6e−5, 4.0e−6, 1.5e−6, and 5.4e−4, respectively). The MPN24 score was particularly useful in improving risk-stratification of DIPSS-intermediate, and MIPSS70-intermediate and high-risk patients. MPN24 is an HSPC-derived gene expression score that is associated with OS independent of clinical and genomic prognostic variables and improves risk stratification in MF.
- 7 May 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (19) , 2238-2251
Open AccessA stem and progenitor cell–derived gene expression signature is prognostic for survival in myelofibrosis
In this study, we hypothesized that transcriptomic features among disease-driving hematopoietic stem and progenitor cells (HSPC) could improve current paradigms for risk stratification in myelofibrosis (MF). Therefore, we performed bulk RNA sequencing (RNA-seq) of blood from 358 patients with MF, split into training and test cohorts. Single-cell RNA-seq data from Lin–CD34+ MF HSPCs were used to guide the development of a prognostic model trained on the bulk RNA-seq data. A NanoString assay was used to validate our final model in 2 independent cohorts of patients with MF. We identified a 24-gene weighted-sum expression score (MPN24) that was prognostic of overall survival (OS). In 2 independent cohorts of 170 and 100 patients with MF, MPN24-high scoring patients had worse 5-year OS compared with MPN24-low scoring patients (25.5% vs 86.9%, hazard ratio [HR] = 9.81, P = 4.0e−11 and 23.5% vs 75.9%, HR, 6.40, P = 1.8e−7, respectively). MPN24-high was also associated with clinical, mutation and karyotypic features known to confer adverse risk in MF. The MPN24 score retained independent prognostic significance in multivariable analysis incorporating these covariates and existing risk stratification models including Dynamic International Prognostic Scoring System (DIPSS), DIPSS plus, Mutation-Enhanced International Prognostic Score System (MIPSS70), and MIPSS70 plus version 2.0, adding significant prognostic value to these risk stratification models (P = 1.6e−5, 4.0e−6, 1.5e−6, and 5.4e−4, respectively). The MPN24 score was particularly useful in improving risk-stratification of DIPSS-intermediate, and MIPSS70-intermediate and high-risk patients. MPN24 is an HSPC-derived gene expression score that is associated with OS independent of clinical and genomic prognostic variables and improves risk stratification in MF.
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
Tet2het dendritic cells do not costimulate CD8 T cells more potently than their wild type counterparts
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
Tet2het dendritic cells do not costimulate CD8 T cells more potently than their wild type counterparts
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
TET2-CH colorectal and melanoma cancer patients show enhanced immune infiltration
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
TET2-CH colorectal and melanoma cancer patients show enhanced immune infiltration
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
CH mutational profile of immunotherapy-treated melanoma patients
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
CH mutational profile of immunotherapy-treated melanoma patients
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
In isotype-control condition, Tet2het TILs are enriched for B cells, naïve CD4 and naïve CD8 T Cells, and MDSCs
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
In isotype-control condition, Tet2het TILs are enriched for B cells, naïve CD4 and naïve CD8 T Cells, and MDSCs
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
CH mutational profile of NCT02644359 patients
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
CH mutational profile of NCT02644359 patients
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
Mice with 20% Tet2-mutant hematopoiesis do not show an attenuation of tumor growth in immunotherapy response rate
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
Mice with 20% Tet2-mutant hematopoiesis do not show an attenuation of tumor growth in immunotherapy response rate
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
Tet2het cells composed the majority of stem and progenitor cells in competitive transplantation experiments
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
Tet2het cells composed the majority of stem and progenitor cells in competitive transplantation experiments
- Open Access
- 19 February 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (8) , 863-876
Glutaredoxin 2 is essential for AML survival through mitochondrial permeability transition pore regulation
Patients with acute myeloid leukemia (AML) have a poor 5-year survival rate, highlighting the need for the identification of new approaches to target this disease. AML is highly dependent on glutathione (GSH) metabolism for survival. Although the metabolic role of GSH is well characterized in AML, the contribution of protein glutathionylation, a reversible modification that protects protein thiols from oxidative damage, remains largely unexplored. Therefore, we sought to elucidate the role of protein glutathionylation in AML pathogenesis. Here, we demonstrate that protein glutathionylation is essential for AML cell survival. Specifically, the loss of glutaredoxin 2 (GLRX2), an enzyme that removes GSH modifications, resulted in selective primary AML cell death while sparing normal human hematopoietic stem and progenitor cells. Unbiased proteomic analysis revealed increased mitochondrial protein glutathionylation upon GLRX2 depletion, accompanied by mitochondrial dysfunction, including impaired oxidative phosphorylation, reduced mitochondrial membrane potential, and increased opening of the mitochondrial permeability transition pore (mPTP). Further investigation identified adenosine triphosphate synthase subunit O (ATP5PO), a key regulator of mPTP opening and a component of the ATP synthase complex, as a critical GLRX2 target. Disruption of ATP5PO glutathionylation partially restored mPTP function and rescued AML cell viability after GLRX2 depletion. Moreover, both genetic and pharmacological inhibition of mPTP opening restored the leukemic potential of primary AML specimens in the absence of GLRX2. By disrupting glutathionylation-dependent mitochondrial homeostasis, this study reveals a novel vulnerability in AML that could inform future therapeutic strategies.
- 19 February 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (8) , 863-876
Open AccessGlutaredoxin 2 is essential for AML survival through mitochondrial permeability transition pore regulation
Patients with acute myeloid leukemia (AML) have a poor 5-year survival rate, highlighting the need for the identification of new approaches to target this disease. AML is highly dependent on glutathione (GSH) metabolism for survival. Although the metabolic role of GSH is well characterized in AML, the contribution of protein glutathionylation, a reversible modification that protects protein thiols from oxidative damage, remains largely unexplored. Therefore, we sought to elucidate the role of protein glutathionylation in AML pathogenesis. Here, we demonstrate that protein glutathionylation is essential for AML cell survival. Specifically, the loss of glutaredoxin 2 (GLRX2), an enzyme that removes GSH modifications, resulted in selective primary AML cell death while sparing normal human hematopoietic stem and progenitor cells. Unbiased proteomic analysis revealed increased mitochondrial protein glutathionylation upon GLRX2 depletion, accompanied by mitochondrial dysfunction, including impaired oxidative phosphorylation, reduced mitochondrial membrane potential, and increased opening of the mitochondrial permeability transition pore (mPTP). Further investigation identified adenosine triphosphate synthase subunit O (ATP5PO), a key regulator of mPTP opening and a component of the ATP synthase complex, as a critical GLRX2 target. Disruption of ATP5PO glutathionylation partially restored mPTP function and rescued AML cell viability after GLRX2 depletion. Moreover, both genetic and pharmacological inhibition of mPTP opening restored the leukemic potential of primary AML specimens in the absence of GLRX2. By disrupting glutathionylation-dependent mitochondrial homeostasis, this study reveals a novel vulnerability in AML that could inform future therapeutic strategies.
- Open Access
- 16 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
Mice with 20% Tet2-mutant hematopoiesis do not show an attenuation of tumor growth in immunotherapy response rate
- 16 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
Mice with 20% Tet2-mutant hematopoiesis do not show an attenuation of tumor growth in immunotherapy response rate